The medical infrastructure in Turkey is substantial with many large hospitals. However, for clinical trials, we need more dedicated places to conduct clinical trials, an institutional…
In Conversation
The Turkish authorities continue to be content with the current [pricing] system because it has been sustained until today. The question the industry is asking itself…
The objective [for Turkey] now should be to implement policies in areas like rare diseases so that we can expedite access to innovative medicines for diseases…
The importance and urgency of developing a vaccine during the COVID-19 pandemic is obvious
Our plan is ambitious and optimistic; we put our faith in the country and will continue to do so.
[Vision 2030] is compelling because it is leading the transformation from an oil-based economy to a knowledge-based economy. In doing so, the country put its healthcare…
Turkey has a unique value proposition, bringing European perfection at an affordable cost, and Novartis has made investments to make the country a quality export launchpad
The days of picking low hanging fruit are over; the only strategies that will be rewarded are those based on deep and long-term investment in local…
We are on board with the idea of including Turkey in more clinical trials. Today, the country is very involved with Bayer's innovative products from the…
In simple terms, Vision 2030 is about moving the country from an oil-based economy to non-oil-based economy, but in reality, it is transforming all aspects of…
Positioning Turkey as a regional hub for the Menarini Group is a sign of senior management’s great confidence in the country and its people, and a…
We have set some goals not only as an industry but as a country: increase the production of high-value products not only in pharma but across…
